Adagene Inc. — FY2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a quarterly filing; the filing does not provide a clear standalone 2023 Q4 income statement or cash-flow breakdown. Financial statements are prepared under U.S. GAAP. Amounts below are in U.S. dollars unless noted.
Business context
Adagene is a clinical-stage biotechnology company developing antibody-based cancer immunotherapies. It has no approved products and has not generated product-sales revenue. Its lead candidate, ADG126, is a masked anti-CTLA-4 antibody in Phase 1b/2 development, with emphasis on combination treatment in metastatic microsatellite-stable colorectal cancer (MSS CRC). Other clinical-stage programs include ADG116, ADG206 and ADG106. Collaboration and licensing revenue helps fund internal research and development.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Licensing and collaboration revenue | $18.1 million | $9.3 million |
| Research and development expense | $36.6 million | $81.3 million |
| Administrative expense | $8.7 million | $11.9 million |
| Operating loss | $23.7 million | $83.9 million |
| Net loss | $18.9 million | $80.0 million |
| Net cash used in operating activities | $28.5 million | $48.6 million |
| Cash and cash equivalents at year-end | $109.9 million | $143.8 million |
| Total borrowings at year-end | $21.9 million | $27.8 million |
Revenue increased about 95%, primarily from Sanofi and Exelixis collaboration and technology-license arrangements; it was not product-sales revenue. The 2023 revenue included $9.6 million recognized under the Exelixis arrangements, including a $3.0 million milestone, and $8.5 million recognized over time under the Sanofi agreement. Management attributed lower R&D spending—down about 55%—to prioritizing ADG126. Administrative expenses fell about 27% following cost controls. Net loss narrowed about 76%; basic and diluted GAAP loss per ordinary share was $0.35, versus $1.48 in 2022.
Operating cash use improved by about $20.2 million year over year. The year-end cash balance declined by $33.8 million; cash used in investing activities was $0.1 million, and financing activities used $5.4 million net. Current assets were $113.4 million and current liabilities were $31.5 million. Borrowings comprised $8.4 million current and $13.5 million long-term. The company reported $4.3 million interest income and $1.1 million interest expense. No operating margin or product gross margin is meaningful to assess from the disclosed business mix and absence of product sales.
Management said existing cash and cash equivalents were expected to fund operations into 2026, subject to assumptions that may prove incorrect. The company also reported $15.1 million of contract liabilities at year-end 2022, which were fully recognized during 2023 as performance obligations were satisfied.
Material changes and unusual items
- R&D expense reductions were broad: spending on preclinical, non-clinical programs fell to $1.0 million from $20.7 million, while ADG126 R&D expense increased to $20.9 million from $19.2 million.
- Other operating income included a one-time compensation payment from a contract manufacturer; the filing reports $3.5 million for 2023 but does not separately state the payment amount.
- Other income was $1.8 million, including government subsidies and an Australian R&D tax incentive. Interest income rose to $4.3 million, primarily due to higher interest rates and larger term deposits.
- Year-end shares outstanding were 55,145,839 ordinary shares, compared with 54,065,709 a year earlier. Share-based compensation was $7.3 million in 2023.
- After year-end, on March 29, 2024, Adagene entered into an at-the-market sales agreement permitting up to $100 million of ADS sales. This potential financing could dilute existing holders.
Outlook, management commentary and principal risks
Management is concentrating resources on ADG126, including continued combination development with pembrolizumab. The company reported that it initiated evaluation of 20 mg/kg loading doses with pembrolizumab and planned further dose expansion, subject to ongoing safety evaluation. These are development plans, not assurance of clinical or regulatory success.
In results presented in January 2024 from an ongoing study, 46 heavily pretreated patients receiving ADG126 plus pembrolizumab had Grade 3 treatment-related adverse events in 5 patients (10.8%), with no Grade 4 or 5 events and treatment discontinuation in 3 patients (6.5%). In the MSS CRC dose-expansion subset, 2 of 12 evaluable patients receiving ADG126 10 mg/kg every three weeks had confirmed partial responses. These small, interim clinical findings are not proof of efficacy; the filing cautions that preliminary data may change with further follow-up and verification.
- Development and funding: No candidate is approved, losses and operating cash outflows are expected to continue, and additional financing may be needed. Financing could dilute shareholders or require concessions on assets or rights.
- Clinical and regulatory uncertainty: Trials may fail, be delayed, or reveal safety issues. The filing describes a prior 2019 FDA clinical hold on ADG116 after a patient death; the hold was later lifted following protocol changes. ADG126 and other candidates remain investigational.
- Manufacturing and collaboration dependence: The company has relied on WuXi Biologics for clinical drug-substance supply, while evaluating alternatives. Partners control aspects of collaborative development and may discontinue programs. Related-party payables to WuXi Biologics were $16.4 million at year-end; 2023 services purchased from WuXi Biologics and WuXi AppTec Group totaled about $2.7 million.
- China and cross-border risks: Adagene is a Cayman Islands holding company with substantial operations in China. PRC regulatory oversight, overseas listing and financing filings, data privacy and cross-border scientific-data rules, foreign-exchange controls, and limits on subsidiary distributions could affect operations, access to funds, or the ADSs. The company said it had not received a regulatory objection to its Nasdaq listing or been subject to a cybersecurity review investigation as of the report date.
- Audit and tax: The PCAOB reported it could inspect China-based audit firms in 2022, but future access is uncertain; loss of access could create HFCAA trading-prohibition risk after two consecutive non-inspection years. Adagene said it was likely a PFIC in 2023 and identified significant risk for 2024 and later years, potentially creating adverse U.S. tax consequences for U.S. investors.
- Other investor considerations: The ADS price may be volatile; the company does not expect near-term dividends. Management concluded internal control over financial reporting was effective at year-end 2023, but the filing has no auditor attestation of that assessment. No material legal proceedings were reported.
Important facts for investors to verify
- Review the audited financial statements and notes for collaboration revenue timing, the one-time manufacturer compensation, borrowing maturities, and related-party balances.
- Check subsequent ADG126 trial updates, including patient numbers, response durability, safety, and whether interim results are confirmed in larger cohorts.
- Monitor cash use, collaboration milestone receipts, the management cash-runway estimate, and any use of the $100 million ATM program.
- Confirm current clinical status, manufacturing supply arrangements, and any changes in partner commitments or China regulatory requirements.
- Consult tax advisers on the company’s potential PFIC status and verify PCAOB inspection status and related HFCAA developments.